0001845314-21-000001.txt : 20210217
0001845314-21-000001.hdr.sgml : 20210217
20210216185401
ACCESSION NUMBER: 0001845314-21-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210217
DATE AS OF CHANGE: 20210216
EFFECTIVENESS DATE: 20210217
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunoRx Pharma, Inc.
CENTRAL INDEX KEY: 0001845314
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-389613
FILM NUMBER: 21641786
BUSINESS ADDRESS:
STREET 1: 1000 N. WEST ST., SUITE 1200
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: 6493324417
MAIL ADDRESS:
STREET 1: 1000 N. WEST ST., SUITE 1200
CITY: WILMINGTON
STATE: DE
ZIP: 19801
D
1
primary_doc.xml
X0708
D
LIVE
0001845314
ImmunoRx Pharma, Inc.
1000 N. WEST ST., SUITE 1200
WILMINGTON
DE
DELAWARE
19801
6493324417
DELAWARE
None
None
Corporation
true
2020
Caroline
Fortier
1000 N. West St., Suite 1200
Wilmington
DE
DELAWARE
19801
Executive Officer
Mark
Cipriano
1000 N. West St., Suite 1200
Wilmington
DE
DELAWARE
19801
Executive Officer
Marc
Riviere
2 Place Alexis Nihon, Suite 902
3500 Blvd de Maisonneuve West
Westmount
A8
QUEBEC, CANADA
H3Z 3C1
Director
Philippe
Tessier
1040 Rue Pierre-Perrault #325
Lewis
A8
QUEBEC, CANADA
G7A 0Z8
Director
Alexandre
Lebeaut
1302 Wakefield Ct.
Southlake
TX
TEXAS
76092
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2020-11-26
false
true
false
0
25437000
2667000
22770000
This offering was made in exchange for (i) $24.77M in total possible cash consideration in five tranches based on developmental milestones and (ii) certain licensing rights to investor's proprietary compound, which were estimated to be valued at $667,000.
false
2
0
0
86000
true
The offering is structured in five tranches of financing, contingent on issuer meeting specific developmental milestones. If the total financing amount is achieved, executive officers and directors will be paid up to $1.2M.
false
ImmunoRx Pharma, Inc.
Juan Felipe Velasquez
Juan Felipe Velasquez
Attorney-in-Fact for Caroline Fortier, CEO
2021-02-16